REBLOZYL® (luspatercept-aamt) is a prescription medicine used to treat anemia (low red blood cells) in adults with myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) who need regular RBC transfusions and have not responded well to or cannot receive an erythropoiesis stimulating agent (ESA).
REBLOZYL is not for use as a substitute for RBC transfusions in people who need immediate treatment for anemia.
It is not known if REBLOZYL is safe or effective in children under 18 years of age.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Learning about the relationship between MDS and anemia may be helpful to better understand your disease.
What is MDS?
MDS are a group of disorders in which the
bone marrow
fails to make enough healthy
red blood cells (RBCs),
white blood cells (WBCs),
or
platelets
and is considered a blood cancer. Bone marrow is the soft tissue that is found in the center of most bones. Bone marrow is the main place where
blood cells
are made.
MDS may be caused by changes to DNA called mutations.
These mutations change the way the cells grow and function. With MDS, some newly formed blood cells become abnormal and do not grow (mature) correctly or do not enter the bloodstream to do their job.
Mature
RBC
Abnormal RBC
The abnormal cells take up space needed for normal bone marrow function. This can lead to your body making too few mature blood cells that may not live as long.
Bone Marrow
The pile up in the bone marrow keeps immature RBCs from growing into mature RBCs. Some of these abnormal immature RBCs are called
ring sideroblasts (RS).
Ring Sideroblast
Your healthcare team will look to see what type of blood cell count is low.
Anemia: Too few RBCs—these are the blood cells that carry oxygen through your body
Possible symptoms:
Neutropenia: Too few WBCs—these are the blood cells that help fight infection
Possible symptoms:
Thrombocytopenia: Too few platelets—these are the blood cells that help stop bleeding, like when you get a cut
Possible symptoms:
Anemia is very common in people with lower-risk MDS. In fact, anemia occurs in up to 9 out of 10 people who have MDS.
Your healthcare team will run certain tests before diagnosing your type of MDS. These tests include taking bone marrow and blood samples to answer the following:
Learning you have MDS can be hard. And you may be worried about what your future holds. You may experience a range of thoughts as you come to terms with your MDS diagnosis. Learning about MDS is the first step in taking control.
After your healthcare team has confirmed that you have MDS, they will give you a risk level score. This score helps your healthcare team understand the chances of your MDS progressing. Your risk score is one important factor. However, it’s not the only one. Your doctor will look at other factors, such as your age, your ability to perform daily tasks, and your recent blood test results. If you are concerned about your risk level score, it may help to talk with other people who have MDS, your healthcare team, or even a counselor.
Based on your risk level score, your healthcare team will choose a treatment approach. Your doctor will recommend a treatment plan based on the information they have.
There are a number of different ways to treat MDS. Here’s a summary of treatment approaches:
Watch-and-wait method
Watch-and-wait method
Watch and wait means being aware of and monitoring your symptoms and blood work for any changes. You will work closely with your healthcare team and have regular visits with them to discuss any changes. You may find it helpful to track these changes to make sure you don’t miss anything during your visits. Be sure to share any changes with your doctor. If after sharing this information your doctor thinks your MDS is getting worse, you will work together on a treatment option that is best for you. Starting treatment–whether to help with symptoms or MDS directly–can be a little scary. However, it’s important to understand that it’s a step toward managing your MDS.
Supportive care
Supportive care
Focuses on treating your symptoms of MDS. One type of this care is RBC transfusions. RBC transfusions add donated RBCs to your body.
Erythropoiesis stimulating agent (ESA)
Erythropoiesis-stimulating agent (ESA)
An ESA is a man-made
hormone given by injection to raise blood cell counts.
Erythroid maturation agent (EMA)
Erythroid maturation agent (EMA)
An EMA helps by developing more mature, working RBCs.
Active treatments for MDS
Active treatments for MDS
Before using these treatments, your healthcare team must decide that they are right for you. These treatments are available if you are in the low- to very high-risk score range. Examples include medicines such as:
It’s important to talk openly with your doctor about what you are looking for from a treatment plan. Talk to your healthcare team after starting any treatment. Tell them how you’re feeling and any new or changing symptoms you’ve experienced. Knowing these options can help you talk with your doctor about your plan.
Here are some questions you may want to ask your healthcare team about treating MDS:
Here are some questions you may want to ask your healthcare team about treating MDS:
When it comes to managing your MDS, it’s important for you to feel like an active part of your treatment journey. You are your best advocate. Asking questions along the way to understand your treatment can help you achieve this.
If your doctor chooses RBC transfusions, be sure to write down your hemoglobin (Hgb) levels and track when you are going for your transfusions. You should also write down the number of RBC units in each transfusion. This can help your healthcare team see how your treatment is working. It’s important that you work with your healthcare team along the way. They are there to give you support and to share resources with you that can help manage MDS.